- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02540044
Supporting Patient Care With Electronic Resource (SuPER) (SuPER)
Supporting Patient Care With Electronic Resource (SuPER): Efficacy of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed project aims to improve the process of making evidence-informed treatment decisions by patients with rheumatoid arthritis (RA) and ultimately, empower patient self-management. Current RA treatment emphasizes: 1) the need for early and aggressive treatment, and 2) the use of a Treat-to-Target approach. Patients often struggle with treatment decisions, however, especially when the options have both benefits and risks. To address this challenge, the investigators have developed a new online decision aid called ANSWER-2 (ANimated, Self-serve, WEb-based, Research Tool: Version 2) for RA patients who are considering a biologic or other new therapy. A unique feature of ANSWER-2 is its ability to individualize how treatment options are presented based on the patient's preferences.
Objective: 1) To evaluate the effectiveness of ANSWER-2 in reducing patients' decisional conflict. 2) To assess the extent to which ANSWER-2 improves patients' knowledge about RA medications and confidence in managing their health. 3) To examine the experiences of patients and rheumatologists in using the ANSWER-2.
The investigators will conduct a proof-of-concept randomized controlled trial with 148 patients with RA. Eligible individuals are those: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic or other new therapy or switching to another agent, and 3) who have internet access. The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own within two days. At the end of the session, a one-page summary will be produced to help them discuss their questions, concerns, and preferred choices with their health care providers. The Control Group will receive The Arthritis Society's online education booklet "Arthritis Medications: A Consumer's Guide". Participants will complete the Decisional Conflict Scale (primary outcome) before and after the intervention (ANSWER-2 or booklet). The following secondary outcome measures will be collected at baseline, 1 month and 2 months: 1) Medication Education Impact Questionnaire (MeIQ), and 2) Partners in Health Scale (PHS). In addition, use of healthcare resources will be collected at 2 months. Participants will also be asked about their medication preferences at Month 1, as well as the shared decision making process in their last appointment, (using the 3-item CollaboRATE scale), at Month 1. Participants who received the ANSWER-2 decision aid and their rheumatologists will be invited to participate in an interview about their experience with the patient decision aid. The investigators will use analysis of variance (ANOVA) to compare between the Intervention Group and Control Group, using the baseline measure as a covariate. An iterative content analysis will be conducted for the qualitative interviews.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jasmina Geldman, MS
- Phone Number: 604-207-4007
- Email: jgeldman@arthritisresearch.ca
Study Contact Backup
- Name: Navi Grewal, MS
- Phone Number: 604-207-4053
- Email: ngrewal@arthritisresearch.ca
Study Locations
-
-
British Columbia
-
Richmond, British Columbia, Canada, V6X2C7
- Recruiting
- Arthritis Research Canada
-
Contact:
- Jasmina Geldman, MS
- Phone Number: 604-207-4007
- Email: jgeldman@arthritisresearch.ca
-
Contact:
- Navi Grewal, MS
- Phone Number: 604-207-4053
- Email: ngrewal@arthritisresearch.ca
-
Principal Investigator:
- Linda Li, PT,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The inclusion criteria are as follows: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic/subsequent entry biologic or switching to another biologic agent, and 3) who have internet access and email.
Exclusion Criteria:
- Patients who do not meet the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ANSWER-2 decision aid
The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days.
At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
|
ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option.
Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
|
Active Comparator: Control Group (TAS Consumer Guide)
The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society.
It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
|
The Arthritis Society Consumer guide pdf.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decisional Conflict Scale
Time Frame: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
The Decisional Conflict Scale (short version) measures personal perceptions of uncertainty in choosing options, factors contributing to uncertainty, and effective decision-making.
It is one-dimensional and has 10 questions and three response categories (yes/no/unsure) used to compute one score.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MeiQ
Time Frame: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
The MeiQ consists of 6 subscales and a total of 29 items.
MeiQ was developed and tested in three different samples of patients with rheumatic conditions on their knowledge of medications.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
Partners in Health Scale
Time Frame: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
The Partners in Health Scale is an 11-item measure, designed to assess self-efficacy, knowledge of RA and treatment, and self-management behaviours such as taking medication appropriately and adopting a healthy lifestyle.
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1, and at month 2)
|
Health Resource Utilization
Time Frame: Change measure (baseline score compared to after using the ANSWER-2 at month 2)
|
The HRU questionnaire was developed for both self and interviewer administration in people with arthritis and other chronic conditions.
It consists of a series of open-ended questions about individuals' visits to health professionals, use of investigative tests, hospital visits, use of medications, purchases of adaptive aids, and estimable productivity loss incurred by the individual and their caregivers due to the his/her health.
|
Change measure (baseline score compared to after using the ANSWER-2 at month 2)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CollaboRATE Scale
Time Frame: Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
a 3-item measure of the shared decision making process
|
Change measure (baseline score compared to after using the ANSWER-2 intervention at month 1)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Linda Li, PhD, Professor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H15-02046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on ANSWER-2 decision aid
-
Massachusetts General HospitalBrigham and Women's Hospital; Arthritis Research Centre of CanadaUnknownRheumatoid ArthritisUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedSurgical Procedure, UnspecifiedUnited States
-
Ottawa Hospital Research InstituteUniversity of Toronto; The Ottawa Hospital; University of OttawaCompleted
-
University of LeedsBaxter Healthcare Corporation; National Health Service, United Kingdom; Foundation... and other collaboratorsCompletedChronic Kidney FailureUnited Kingdom
-
Massachusetts General HospitalCompletedCoronary Artery Disease | Stable AnginaUnited States
-
University Hospital HeidelbergInnovationsfonds des Gemeinsamen Bundesausschusses, GermanyCompletedPatient Decision Aid | Treatment As UsualGermany
-
Massachusetts General HospitalUnknownDecision Making | Video Decision AidsUnited States
-
Kaiser PermanenteFoundation for Informed Medical Decision MakingCompletedObesity | Obesity, Morbid | Bariatric Surgery | Decision AidsUnited States
-
Case Comprehensive Cancer CenterCompletedProstate CancerUnited States
-
Duke UniversityFoundation for Informed Medical Decision MakingCompletedOsteoarthritisUnited States